Sato Pharmaceutical Co., Ltd.

Privately held: no public share price · Japan

Assets

(3 total)
3Total Assets
3Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
berdazimer(Zelsuvmi)
Approved
Nitric oxide releaseSmall molecule
Molluscum Contagiosum
Approved
PDE4Small molecule
PsoriasisSeborrheic Dermatitis
Approved
PDE4Small molecule
Atopic DermatitisPsoriasis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
April 2028 (1)
Roflumilast (Zoryve)Phase 3Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Est. primary completion 2028-04-27 · NCT07916480 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

23 February 2027FDA action dateRoflumilast (Zoryve)PDUFA target date 23 Feb 2027 for Zoryve cream 0.05% in infant AD
US, FDA · Source ↗

Recent

8 July 2026Filing acceptedRoflumilast (Zoryve)FDA accepts sNDA for Zoryve cream 0.05% in infant atopic dermatitis
US, FDA · Source ↗
29 June 2026ApprovalRoflumilast (Zoryve)FDA approves ZORYVE cream 0.3% for plaque psoriasis in children as young as 2
US, FDA · Source ↗

Financial reports

No financial reports recorded.